Zacks Research Forecasts Weaker Earnings for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Zacks Research dropped their FY2026 earnings per share (EPS) estimates for Avanos Medical in a research report issued to clients and investors on Tuesday, December 31st. Zacks Research analyst R. Department now expects that the company will earn $1.99 per share for the year, down from their previous forecast of $2.00. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share.

Separately, StockNews.com downgraded Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 3rd.

Avanos Medical Trading Down 1.8 %

NYSE AVNS opened at $15.55 on Friday. The stock has a market cap of $714.63 million, a P/E ratio of 45.74 and a beta of 0.95. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. Avanos Medical has a 12 month low of $15.51 and a 12 month high of $25.36. The stock’s fifty day moving average price is $18.33 and its 200-day moving average price is $21.04.

Hedge Funds Weigh In On Avanos Medical

A number of large investors have recently bought and sold shares of AVNS. The Manufacturers Life Insurance Company boosted its position in shares of Avanos Medical by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 17,137 shares of the company’s stock worth $341,000 after buying an additional 590 shares during the period. KBC Group NV raised its stake in Avanos Medical by 63.0% in the third quarter. KBC Group NV now owns 2,833 shares of the company’s stock valued at $68,000 after buying an additional 1,095 shares in the last quarter. New York State Teachers Retirement System raised its stake in Avanos Medical by 2.0% in the third quarter. New York State Teachers Retirement System now owns 72,294 shares of the company’s stock valued at $1,737,000 after buying an additional 1,388 shares in the last quarter. Quarry LP acquired a new stake in Avanos Medical in the third quarter valued at $42,000. Finally, Foundry Partners LLC raised its stake in Avanos Medical by 1.1% in the third quarter. Foundry Partners LLC now owns 163,030 shares of the company’s stock valued at $3,918,000 after buying an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.